Source comparison
IGF-1 LR3 Dosage Protocols: Research Applications Comparison
Research objectives determine dosing strategy. The table below compares protocols used in published studies and institutional research settings, categorized by experimental focus. Acute anabolic signaling assays (Akt/mTOR/ERK phosphorylation) 60–100 mcg Single
This comparison does not assign a generated winner or score.
- Research objectives determine dosing strategy. The table below compares protocols used in published studies and institutional research settings, categorized by experimental focus.
- Acute anabolic signaling assays (Akt/mTOR/ERK phosphorylation)
- 60–100 mcg
- Single dose or 1×/day for 3–5 days
- 1–5 days
- Subcutaneous or IV
- High-dose, short-duration protocol maximizes receptor activation for endpoint measurement within narrow observation window
- Chronic tissue growth or hypertrophy models
- 20–40 mcg
- 1×/day or every other day
- 3–8 weeks
- Subcutaneous
- Lower dose minimizes receptor desensitization; every-other-day dosing may be superior for sustained response
- Wound healing or tissue repair studies
- 30–60 mcg
- 1×/day
- 7–21 days
- Local (near injury site) or subcutaneous
- Mid-range dose supports collagen synthesis and fibroblast proliferation without excessive systemic exposure
- Metabolic or glucose utilization studies
- 20–50 mcg
- 1×/day or 2×/week
- 2–6 weeks
- Dose and frequency must account for insulin cross-reactivity; fasted-state dosing reduces confounding
- Neurological or neuroprotection models
- 10–30 mcg
- 7–28 days
- Intracerebroventricular (ICV) or subcutaneous
- Lower systemic doses used when central effects are the focus; ICV administration bypasses blood-brain barrier limitations
- The 'every other day' dosing strategy in chronic protocols reflects emerging evidence that pulsed exposure maintains receptor sensitivity better than continuous daily dosing. A 2019 study published in the Journal of Endocrinology demonstrated that IGF-1R downregulation in skeletal muscle occurs within 10–14 days of daily supraphysiological IGF-1 exposure, but the same cumulative dose delivered every 48 hours produced sustained receptor expression for up to six weeks. The mechanism is receptor trafficking: continuous ligand binding promotes internalization and lysosomal degradation of IGF-1R, whereas pulsed exposure allows receptors to recycle to the cell surface between doses. For researchers designing multi-week protocols, alternating-day dosing at 40–50 mcg may outperform daily dosing at 20–25 mcg despite identical weekly exposure.